Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Maraviroc: pharmacokinetics and drug interactions Abel S; Back DJ; Vourvahis MAntivir Ther 2009[]; 14 (5): 607-18Maraviroc is a potent selective CCR5 antagonist and is the first of this new class of oral agents to be approved for the treatment of CCR5-tropic HIV type-1. Maraviroc is extensively metabolized by CYP3A4, with renal clearance accounting for approximately 23% of total clearance. The half-life of maraviroc is approximately 16 h. Maraviroc does not inhibit any of the major CYP450 enzymes at clinically relevant doses and it has not shown any clinically relevant effects on plasma concentrations of other agents; hence, no dose adjustments of coadministered agents are required. Maraviroc exposure is altered by agents that modulate the activity of CYP3A4 and, in some circumstances, maraviroc dose adjustment is necessary. This article aims to review all pharmacokinetic and drug interaction data available for maraviroc, and to provide a comprehensive summary of the dose adjustment recommendations for maraviroc when coadministered with agents from all classes of antiretroviral therapy as well as other commonly coadministered agents.|*Anti-HIV Agents/administration & dosage/metabolism/pharmacokinetics[MESH]|*Anti-Infective Agents/administration & dosage/metabolism[MESH]|*CCR5 Receptor Antagonists[MESH]|*Reverse Transcriptase Inhibitors/administration & dosage/metabolism[MESH]|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Clinical Trials as Topic[MESH]|Cyclohexanes/administration & dosage/metabolism/*pharmacokinetics[MESH]|Drug Interactions[MESH]|Drug Therapy, Combination[MESH]|Female[MESH]|HIV Infections/*drug therapy/virology[MESH]|HIV-1/drug effects[MESH]|Humans[MESH]|Male[MESH]|Maraviroc[MESH]|Middle Aged[MESH]|Triazoles/administration & dosage/metabolism/*pharmacokinetics[MESH]|Young Adult[MESH] |